Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

Rhea-AI Summary

Gilead Sciences (GILD) announced a $7.6 million grant funding initiative under the Toward Health Equity Oncology Grant™ to 24 U.S.-based organizations. This program focuses on addressing health inequity in breast cancer care through evidence-based interventions like patient navigator and cultural competency training. With breast cancer affecting more women in the U.S. than any other cancer (excluding skin cancer), this initiative aims to combat disparities, particularly among people of color. The funding builds on a prior $5.7 million support provided to 21 organizations in 2022, expanding efforts to close gaps in care for historically neglected communities.

Positive

• Awarding $7.6 million to 24 organizations enhances Gilead's commitment to health equity.
• Focus on addressing barriers in breast cancer care can improve community health outcomes.
• The initiative targets historically neglected communities, potentially increasing Gilead's positive public perception.

Negative

• None.

– Toward Health Equity Oncology Grant™ Supports Initiatives to Break the Cycle of Health Inequity –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity (THE) Oncology Grant™. The funding will support evidence-based interventions that address barriers to care and social determinants of health including patient navigator training, cultural competency training, and services combating barriers such as transportation.

“Gilead is committed to advancing health equity and supporting these vital patient advocacy organizations working to close gaps in breast cancer care,” said Deborah H. Telman, Executive Vice President, Corporate Affairs and General Counsel, Gilead Sciences. “We believe our Toward Health Equity Oncology Grant awards contribute important new understanding to advance and care for anyone living with breast cancer. We look forward to seeing their dynamic, innovative programs come to life.”

Breast cancer affects more American women than any other type of cancer, besides skin cancer.¹ But due to social, environmental, and economic disparities, people of color are at increased risk of developing or dying from breast cancer.² In 2023, an estimated 300,000 women will be diagnosed with breast cancer in the U.S. and more than 43,000 women will die from breast cancer.³

The 2023 funding will support evidence-based interventions that focus on patient navigation and digital/mobile interventions to improve health equity. All 2023 grantees were chosen based on several criteria including their ability to create measurable and sustainable change toward health equity.

THE Oncology Grant builds on Gilead’s 2022 program, which provided $5.7 million in grants to 21 U.S. organizations for programs working to advance health equity for Black people impacted by triple-negative breast cancer. The new grantees serve historically neglected and underrepresented communities including Hispanic, Jewish, LGBTQIA, Indigenous American, and others, and will work to address access disparities in the treatment of breast cancer.

The 2023 THE Oncology Grant awardees include:

• Asociación Latina De Asistencia Y Prevención Del Cáncer De Mama
• Association of Community Cancer Centers
• Coalition of Blacks Against Breast Cancer
• Family Reach Foundation
• Franklin Square Hospital Center, Inc.
• George Washington University
• Harris County Hospital District Foundation
• Mary Bird Perkins Cancer Center
• New Orleans Musicians Assistance Foundation
• Nueva Vida Inc.
• Patient Advocate Foundation Inc.
• Shanti Project Inc.
• Share Self-Help For Women With Breast Or Ovarian Cancer, Inc.
• Sharsheret Inc.
• Sisters Working It Out NFP
• St. Vincent Hospital
• Susan G Komen Breast Cancer Foundation
• The Ellie Fund
• UC Davis, Comprehensive Cancer Center, Center for Advancing Cancer Health Equity
• Vietnamese American Cancer Foundation
• Virtua Health Foundation, Inc.
• Women’s Cancer Care and Research Program (WeCARE) at UC Davis
• Women’s Cancer Resource Center
• Young Survival Coalition, Inc.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, inflammation and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead’s medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative^® to community organizations that are working to combat HIV in the U.S. South. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

¹ Breast Cancer Statistics. The American Society of Clinical Oncology. Breast Cancer: Statistics | Cancer.Net. Last accessed January 31, 2023.
² Cancer Disparities. The National Cancer Institute. Cancer Disparities - NCI. Last accessed January 31, 2023.
³ Key Statistics for Breast Cancer. The American Cancer Society. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html, last accessed January 31, 2023.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230131006146/en/

Hayley Home, Media

public_affairs@gilead.com

Meaghan Smith, Media

public_affairs@gilead.com

Source: Gilead Sciences, Inc.

FAQ

What is the Toward Health Equity Oncology Grant by Gilead Sciences?

The Toward Health Equity Oncology Grant is a funding initiative by Gilead Sciences aimed at supporting community organizations to address barriers to breast cancer care, with a total of $7.6 million awarded in 2023.

How much funding did Gilead Sciences provide in 2023?

In 2023, Gilead Sciences awarded $7.6 million in grants to support health equity initiatives related to breast cancer.

Which organizations received funding from Gilead's Oncology Grant?

The funding went to 24 organizations, including the Susan G. Komen Breast Cancer Foundation, Mary Bird Perkins Cancer Center, and Coalition of Blacks Against Breast Cancer.

What are the goals of Gilead's health equity initiative?

Gilead's health equity initiative aims to reduce disparities in breast cancer care, focusing on patient navigation and cultural competency.

How did Gilead's 2023 grant funding compare to 2022?

In 2022, Gilead awarded $5.7 million to 21 organizations for similar health equity initiatives, indicating an increase in funding and support in 2023.